Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients

Fig. 2

Levels of a procalcitonin (PCT) and b C-reactive protein (CRP) over time within 6 days prior to and 10 days following cessation of dexamethasone (DEXA) in the group of patients treated with neither dexamethasone nor tocilizumab (D−T− group) as well as in the D+T− and D+T+ groups. Day of cessation of dexamethasone was designated day 0 (alignment day). Data of the D−T− group were aligned on the median alignment day, which was day 9 following ICU admission. Data are presented as geometric mean with 95% confidence intervals. p values were calculated using mixed-models analyses (time × group interaction factor). p values left and right below each panel reflect between-group differences in kinetics from day − 6 until day 0 and from day 0 until day 10, respectively. Colored diamonds reflect p values of < 0.05 between the corresponding groups (D−T− light blue, D+T− dark blue, D+T+ orange) on the individual timepoint, calculated using Sidak’s post-hoc multiple comparisons tests. D−T−: patients treated with neither dexamethasone nor tocilizumab, D+T−: patients treated with dexamethasone but no tocilizumab, D+T+: patients treated with both drugs

Back to article page